Alternative stroke drugs were linked to fewer repeat strokes in a genetic subgroup
A pooled analysis favored ticagrelor/prasugrel over clopidogrel for recurrent stroke, while uncertainty remained about bleeding.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Among patients with a previous ischemic stroke or transient ischemic attack who carried these variants, ticagrelor/prasugrel was associated with fewer recurrent strokes and combined vascular events than clopidogrel. Bleeding did not differ significantly, but that uncertainty does not establish equal safety or rule out a meaningful difference.
This abstract-based account lacks follow-up duration, absolute event rates and separate drug estimates; it cannot establish how each alternative compares individually.
What researchers found
Recurrent stroke risk
Ticagrelor/prasugrel versus clopidogrel in variant carriers: estimated risk was 0.76 times the clopidogrel risk; the confidence interval spans 0.64–0.90 times that risk. These are relative comparisons, not percentage-point reductions. Follow-up and absolute event rates were not reported.
Who the results concern
The analysis addressed preventing another stroke in patients with particular gene variants. Its findings concern that defined group and cannot be assumed to apply to everyone taking antiplatelet medicines.
What bleeding results mean
The bleeding confidence interval included both lower and higher risk with the alternative medicines. A statistically nonsignificant comparison leaves uncertainty about the direction and size of any difference.
The original publication
Genotype-guided ticagrelor/prasugrel versus clopidogrel therapy in stroke patients with CYP2C19 loss of function alleles: a systematic review and meta-analysis.
Biswas M, Murad MA, Ershadian M et al.
Pharmacogenomics · 2025
- PubMed ID
- 41450128
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.